Age-Related Macular Degeneration

News Age-Related Macular Degeneration (AMD)

Wissenschaftspreis für Dr. Aysegül Tura Aktuell: Deutsche Ophthalmologische Gesellschaft zeichnet hochkarätige Veröffentlichungen zu neuen Therapieansätzen bei Netzhauterkrankungen aus: Wissenschaftspreis der Stiftung Auge für Dr. Aysegül Tura (Universitäts-Augenklinik Lübeck)

Durchsuchen Sie hier die Seiten zur altersbedingten Makuladegeneration:

Geben Sie beliebige Suchbegriffe ein (AMD, Therapie, Diagnose, Nahrungsergänzungsmittel...)

Nov. 28, 2012

Bayer's eye drug Eylea approved in Europe

One of Eylea’s key selling points will be its less frequent dosing. Bayer’s drug is given every two months after three initial monthly injections, compared to monthly Lucentis injections.

Read more: Bayer's eye drug Eylea approved in Europe

Nov. 18, 2011

FDA approves Eylea for eye disorder in older people

The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.

Read more: FDA approves Eylea for eye disorder in older people

15.11.2011

International AMD Expert Summit convened in Berlin to improve treatment and outcomes for wet age-related macular degeneration

An international group of fifteen expert ophthalmologists have been convened in Berlin, Germany by the nonprofit Angiogenesis Foundation to share key perspectives and discuss strategies for improving the advocacy, treatment, and vision outcomes for 'wet' form of age-related macular degeneration (AMD), the most common form of blindness over the age of 50 in developed nations.

Read more: International AMD Expert Summit convened in Berlin to improve treatment of Wet AMD

October 05, 2011: Can QLT catch the eye with trial retina drug?

Can QLT catch the eye with trial retina drug?

Canadian eye drug developer QLT Inc. (QLT-T6.980.091.31%) has had its share of pain, with setbacks for a drug delivery system and slowing growth for Visudyne, its main drug, leaving investors to hope an experimental retinal diseases drug can get growth back on track.

...read more

July 13, 2011: Positive Animal Studies for Novel Squalamine Eye Drop for Wet-AMD

Positive Animal Studies for Novel Squalamine Eye Drop for Wet-AMD

Ohr Pharmaceutical today announced positive results from two critical animal studies on the recently announced Squalamine eye drop formulation for the treatment of wet-age related macular degeneration ("wet-AMD").

...read more

5th April 2011, MailOnline: The beam of energy that could save you from blindness

The beam of energy that could save you from blindness

A hand-held device that fires sound waves into the eye could help prevent age-related macular degeneration (AMD), a leading cause of blindness.

The gadget uses the waves to help drugs get into the eye without the need for painful injections.

...read more

March 24, 2011, Georgetown University Medical Center
Stem Cell Therapy for Age-Related Macular Degeneration

Stem Cell Therapy for Age-Related Macular Degeneration - A Step Closer to Reality

The notion of transplanting adult stem cells to treat or even cure age-related macular degeneration has taken a significant step toward becoming a reality.

...read more

15.03.2011 newsmax.com.: Age Related Macular Degeneration: Top 5 Drugs That Work

Age Related Macular Degeneration: Top 5 Drugs That Work

Age related macular degeneration is a medical condition that results in distortion or loss of vision in the macula or center of the visual field in older adults due to damage to the retina. It is of two forms; "dry" and "wet".

...read more

09.03.2011 Lpath, Inc.: Lpath Granted Another Key U.S. Patent Related to iSONEP and ASONEP Drug Programs

Lpath Granted Another Key U.S. Patent Related to iSONEP and ASONEP Drug Programs

Lpath will soon initiate two iSONEP Phase II trials: The PEDigree Study will evaluate the safety and efficacy of iSONEP in patients with RPE Detachment (PED), for which there is no approved drug, and the Nexus Study will evaluate the safety and efficacy in wet-AMD patients without PED. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP.

...read more

February 7, 2011 CBS: Macular Degeneration: Will Discovery Bring Cure for Blindness?

Macular Degeneration: Will Discovery Bring Cure for Blindness?

There's still no cure for macular degeneration, an incurable eye disease that is the leading cause of blindness among older people.

Is that about to change?

...read more: Macular Degeneration: Will Discovery Bring Cure for Blindness?

24.11.2010 Current Research: Lutein, Zeaxanthin and Omega-3 Fatty Acids are Essential for Keeping Eyes Healthy

Current Research: Lutein, Zeaxanthin and Omega-3 Fatty Acids are Essential for Keeping Eyes Healthy

Nutritional Supplements are Recommended at an Older Age
current scientific review article has confirmed that an optimal supply of the carotenoids lutein and zeaxanthin, as well as the omega-3 fatty acids DHA and EPA, is essential for keeping our eyes healthy. The authors emphasise the potential of these nutrients for protection of the retinal cells and the prevention and treatment of age-related degenerative eye diseases, such as macular degeneration (AMD) in the elderly.

...read more

medindia.net, October 30, 2009: Cataract Surgery may Benefit AMD Patients at All Stages

Cataract Surgery may Benefit AMD Patients at All Stages

Cataract surgery improved vision in patients with any stage -from mild to advanced- AMD in the first study to include an adequate number of advanced AMD patients. Data was obtained from the multicenter, prospective Age-Related Eye Disease Study (AREDS)

...more

Tuft University, June 18, 2009: Omega-3 fatty acids appear to impact AMD progression

Omega-3 fatty acids appear to impact AMD progression

Omega-3 fatty acids found in fatty fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD), but the benefits appear to depend on the stage of disease and whether certain supplements are taken, report researchers at the Laboratory for Nutrition and Vision Research (LNVR), Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts University.

...more

HealthDay News, Feb 05, 2009: Cataract Surgery Doesn't Worsen AMD

Cataract Surgery Doesn't Worsen AMD

Cataract surgery doesn't hasten vision loss in people with age-related macular degeneration (AMD).

That's the conclusion of a new study that challenges the findings of several large epidemiological studies that suggested a link between cataract surgery and accelerated AMD progression.

...more


Ferienhof am Ostseestrand

Urlaub Ferienhof Glücksburg-Holnis

7 Ferienwohnungen sind in diesem Ferienhof mit Reitbetrieb am Strand Holnis untergebracht. Alle Ferienwohnungen sind mit SAT-TV ausgestattet. Jede Wohnung verfügt über eine gemütliche Eßecke und Sitzgarnitur. Ein Duschbad gehört ebenfalls zu jeder Ferienwohnung. Großer Garten, Grillhütte und Spielplatz sind am Haus!